-
Cantor Analysts Think Cerus Could Hit $7 On 'Catalysts' Coming
Wednesday, October 7, 2015 - 9:55am | 261Cerus Corporation (NASDAQ: CERS) shares are up 18 percent since April, when they touched a low of $3.86. Cantor Fitzgerald’s Caroline Corner maintained a Buy rating on the company, with a price target of $7. Several catalysts in late 4Q15 and 1Q16 are expected to boost the company...
-
3 Medical Tech Trading Ideas With Upcoming Catalysts
Tuesday, September 29, 2015 - 9:34am | 560Caroline Corner, an analyst at Cantor Fitzgerald that covers medical technology highlighted three companies with upcoming catalysts. The three names are: Alimera Sciences Inc (NASDAQ: ALIM), Cerus Corporation (NASDAQ: CERS), and Intersect ENT Inc (NASDAQ: XENT). Corner stated all three...
-
Glaukos Patent Dispute Is A Non-Event, So 'Stop Worrying' Says Analyst
Tuesday, September 22, 2015 - 8:56am | 334Glaukos Corp. (NYSE: GKOS) has seen a 12.62 percent decline in its share price over the past three months. Caroline Corner of Cantor Fitzgerald has maintained a Buy rating and price target of $37 on the company. Corner believes that despite the patent rulings not being in favor of Glaukos...